| FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia (NCT04714372) | Masonic Cancer Center, University of Minnesota | 2021-11-03 |
| Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors (NCT05035706) | M.D. Anderson Cancer Center | 2021-06-30 |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation (NCT04628338) | Sawa Ito, MD | 2021-03-08 |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL (NCT04260022) | Ascentage Pharma Group Inc. | 2020-01-09 |
| Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland (NCT05363488) | Pfizer | 2019-05-01 |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies (NCT03638206) | Shenzhen BinDeBio Ltd. | 2018-03-01 |
| Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery (NCT02955043) | University of Wisconsin, Madison | 2016-12-22 |
| NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents (NCT02763475) | Instituto de Investigación Hospital Universitario La Paz | 2016-05-01 |
| Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (NCT03659084) | Hospices Civils de Lyon | 2016-04-01 |
| Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation (NCT02719821) | University of Wisconsin, Madison | 2016-03-01 |
| Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine (NCT02489929) | Assistance Publique Hopitaux De Marseille | 2015-08-01 |
| Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT (NCT01779882) | University Hospital, Basel, Switzerland | 2013-01-01 |
| Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies (NCT01760655) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-12-24 |
| Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies (NCT01643603) | Barbara Ann Karmanos Cancer Institute | 2012-05-01 |
| Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia (NCT01380756) | Amgen | 2011-10-04 |
| Genome-wide Pharmacogenetic Candidate Gene Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Myeloid Leukemia With Normal Karyotype (NCT01066338) | Samsung Medical Center | 2010-02-01 |
| Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia (NCT01066286) | Samsung Medical Center | 2010-02-01 |
| Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor (NCT00967343) | Kiadis Pharma | 2009-08-01 |
| Study of IMC-EB10 in Participant With Leukemia (NCT00887926) | Eli Lilly and Company | 2009-06-01 |
| Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia (NCT00543972) | Sanofi | 2007-09-01 |
| Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) (NCT00422890) | Technische Universität Dresden | 2007-01-01 |
| Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia (NCT00497991) | AstraZeneca | 2006-05-01 |
| Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia (NCT00126893) | Celgene Corporation | 2005-10-01 |
| A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups (NCT00521664) | Technische Universität Dresden | 2004-09-01 |
| Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents (NCT00111345) | University Hospital Muenster | 2004-03-01 |
| Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML) (NCT00114764) | Amgen | 2003-03-01 |
| HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies (NCT00001748) | National Heart, Lung, and Blood Institute (NHLBI) | 1998-06-01 |
| Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults (NCT00001637) | National Heart, Lung, and Blood Institute (NHLBI) | 1997-09-29 |